![]() Copies of the preliminary prospectus relating to the proposed offering may be obtained, when available, from: Goldman Sachs & Co. The proposed offering will be made only by means of a prospectus. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Ī registration statement relating to these securities has been filed with the SEC but has not yet become effective. ![]() LLC, SVB Leerink and Evercore ISI are acting as joint book-running managers for the proposed offering. All of the shares in the proposed offering are to be sold by 4D Molecular Therapeutics. 4D Molecular Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock offered in the proposed offering. 26, 2021 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it has commenced an underwritten public offering of 4,500,000 shares of its common stock.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |